Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease

BMC Complementary and Alternative Medicine

Maha M Arafah¹  Aida A Korish² 

[1] Pathology Department, College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia;Physiology Department (29) College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Saudi Arabia

关键词: Rats;    Oxidative stress;    Hyperlipidemia;    Insulin resistance;    High-fat diet;    Steatohepatitis;    Non-alcoholic fatty liver disease;    Camel milk;   

Others  :  1220896
DOI  :  10.1186/1472-6882-13-264

 received in 2013-03-15, accepted in 2013-10-07,  发布年份 2013

【 摘 要 】

Background

Camel milk (CM) is gaining increasing recognition due to its beneficial effects in the control and prevention of multiple health problems. The current study aimed to investigate the effects of CM on the hepatic biochemical and cellular alterations induced by a high-fat, cholesterol-rich diet (HCD), specifically, non-alcoholic fatty liver disease (NAFLD).

Methods

Seventy male Wistar rats were divided into four groups: the Control (C) Group fed a standard diet; the Control + camel milk (CCM) Group fed a standard diet and CM, the Cholesterol (Ch) Group fed a HCD with no CM, and the Cholesterol + camel milk (ChM) Group fed a HCD and CM. The following parameters were investigated in the studied groups; basal, weekly random and final fasting blood glucose levels, intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT), serum insulin, serum lipids, liver functions, lipid peroxidation products, the antioxidant activity of catalase (CAT) and the levels of reduced glutathione (GSH). In addition, HOMA-IR as an index of insulin resistance (IR) and the histopathology of the hepatic tissue were assessed.

Results

The Ch Group developed features similar to those of non-alcoholic steatohepatitis (NASH), characterized by hepatic steatosis; inflammatory cellular infiltration in liver tissue; altered liver functions; and increased total cholesterol, triglycerides, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, atherogenic index (AI), blood glucose, IR, and malondialdehyde (MDA) levels. Additionally, feeding the HCD to animals in the Ch Group decreased CAT activity and the GSH and high-density lipoprotein (HDL) cholesterol levels. Camel milk intake for eight weeks decreased hepatic fat accumulation and inflammatory cellular infiltration, preserved liver function, increased the GSH levels and CAT activity, decreased the MDA levels, and ameliorated the changes in the lipid profile, AI, and IR in animals from the ChM Group.

Conclusions

CM has a unique composition that is rich in minerals; vitamins, insulin and insulin-like protein, and it increased HDL-cholesterol and ameliorated the biochemical and cellular features of NAFLD in rats that received a HCD. The antioxidant effect of CM is a likely mechanism for the altered metabolism and absorption of HCD in the presence of CM. Regular consumption of CM could provide a natural way to protect against NAFLD induced by a high-fat diet.

【 授权许可】

   
2013 Korish and Arafah; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Brunt E: Nonalcoholic steatohepatitis. Semin Liver Dis 2004, 24:3-20.
• [2]Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R: Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatol 2010, 51:595-602.
• [3]Cusi K: Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 2009, 13:545-563.
• [4]Malhi H, Gores GJ: Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:360-369.
• [5]Mukundh NB, Muralidharan P, Balamurugan G: Antihyperlipidemic activity of Pedalium murex (Linn) fruits on high fat diet fed rats. Int J Pharmacol 2008, 4:310-313.
• [6]Lev E: Traditional healing with animals (zootherapy): medieval to present-day Levantine practice. J Ethno pharmacol 2003, 86:107-118.
• [7]WHO, IUCN, WWF: Guidelines on the Conservation of Medicinal Plants Gland. Switzerland: The World Conservation Union (IUCN), in partnership with The World Health Organization (WHO) and World Wide Fund for Nature (WWF); 1993.
• [8]National Center for Complementary and Alternative Medicine (NCCAM): What Is Complementary and Alternative Medicine?. National Institutes of Health; 6 Feb. 2012. Web. 29 May 2012. http://nccam.nih.gov/health/whatiscam webcite
• [9]Gorakh MD, Sena DC, Jain VK, Sahani MS: Therapeutic utility of camel milk as nutritional supplement against multiple drug resistant patients. In: Proc 2nd Intl Camelid Conf Agro economics of Camelid Farming. Almaty 2000, 9:99.
• [10]Yateem A, Balba MT, Al Surrayai T, Al Mutairi B: Al –Daher: Isolation of lactic acid bacteria with probiotic potential from camel milk. Int J Dairy Sci 2008, 3:194-199.
• [11]Al-Awadi FM, Srikumar TS: Trace elements and their distribution in protein fractions of camel milk in comparison to other commonly consumed milks. J Dairy Res 2001, 68:463-469.
• [12]El Agamy EI, Nawar M, Shamsia SM, Awad S, Haenlein GF: Are camel milk proteins convenient to the nutrition of cow milk allergic children. Small Ruminant Res 2009, 82:1-6.
• [13]Al-Hashem F, Dallak M, Bashir N, Abbas M, Elessa R, Khalil M, Al-Khateeb M: Camel's milk protects against cadmium chloride induced toxicity in white albino rats. Am J Pharmacol and Toxicol 2009, 4:107-117.
• [14]El Agamy EI, Ruppanner R, Ismail A, Champagne CP, Assaf R: Antibacterial and antiviral activity of camel milk protective proteins. J Dairy Res 1992, 59:169-175.
• [15]Rao RB, Gupta RC, Dastur NN: Camel’ milk and milk products. Ind J Dairy Sci 1970, 23:71-78.
• [16]Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, Panwar RB, Sahani MS: Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan. India Diabetes Res Clin Pract 2007, 76:290-296.
• [17]Agrawal RP, Swami SC, Beniwal R, Kochar DK, Sahani MS, Tuteja FC, Ghouri SK: Effect on camel milk on glycemic control, lipid profile and diabetes quality of life in type-1 diabetes: A randomized prospective controlled cross over study. Indian J Anim Sci 2003, 73:1105-1110.
• [18]Al Haj OA, Al Kanhal HA: Compositional, technological and nutritional aspects of dromedary camel milk. In Dairy J 2010, 20:811-821.
• [19]Quan S, Tsuda T, Miyamoto T: Angiotensin 1- converting enzyme inhibitory peptides in skim milk fermented with Lactobacillus helveticus 130B4 from camel milk in Inner Mongolia, China. J Sci Food Agric 2008, 88:2688-2692.
• [20]Majeed NA: Corrective effect of milk of camel on some cancer biomarkers in blood of rats intoxicated with aflatoxin B. J Saudi Chem Soc 2005, 9:253-264.
• [21]Khan AA, Alzohairy MA: Hepatoprotective effects of camel milk against CCl4-induced hepatotoxicity in rats in rats. Asian J Biochem 2011, 6:171-180.
• [22]Elayan AA, Sulieman AM, Saleh FA: The hypocholesterolemic effect of Gariss and Gariss containing bifidobacteria in rats fed on a cholesterol-enriched diet. Asian J Biochem 2008, 3:43-47.
• [23]Ming Z, Xiao-Yan L, Jing L, Zhi-Gang X, Li C: The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008 2008, 2008:704-745.
• [24]Otero P, Bonet B, Herrera E, Robano A: Development of atherosclerosis in the diabetic BALB/c mice prevention with vitamin E administration. Atherosclerosis 2005, 182:259-265.
• [25]Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder MF: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993, 38:578-582.
• [26]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of LDL cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [27]Suanarunsawat T, Ayutthaya WDN, Songsak T, Rattanamahaphoom J: Anti-lipidemic actions of essential oil extracted from Ocimum sanctum L. leaves in rats fed with high cholesterol diet. J Appl Biomed 2009, 7:45-53.
• [28]Yagi K: Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 1998, 108:101-106.
• [29]Johansson LH, Borg LAH: A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem 1988, 174:331-336.
• [30]Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
• [31]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [32]Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN): Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53(3):810–-820.
• [33]Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL: Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int 2013, 12(Suppl.2):125-135.
• [34]Ghiyâth Hasan al-Ahmad: Tibb al-Nabawî fî Daw' al-'Ilm al-Hadîth (2:215) and Le DROMADAIRE: Un monde de soif. http://www.abc.se/home/m9783/ir/f/Camel%20Milk.html webcite (in French)
• [35]Jensen MD: Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93:S57-S63.
• [36]Kojda G, Harrison D: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Car vas Res 1999, 43:562-571.
• [37]Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ: Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005, 3:384-389.
• [38]Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatol 2007, 45:1366-1374.
• [39]Schäffler A, Schölmerich J, Büchler C: Mechanisms of disease: adipocytokines and visceral adipose tissue–emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastro- enterol Hepatol 2005, 2:273-280.
• [40]Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatol 2004, 40:46-54.
• [41]Drotman RP, Lawhorn GT: Serum enzymes as indicators of chemical induced liver damage. Drug Chem Toxicol 1978, 1:163-171.
• [42]Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
• [43]Abu-Lehia IH: Physical and chemical characteristic of camel’s milk fat and its fractions. Food Chem 1989, 34:261-271.
• [44]Beg OU, Bahr-Lindstrom HV, Zaidi ZH, Jornvall H: Characterization of a camel milk protein rich in proline identifies a new beta casein fragment. Regul Pept 1986, 15:55-61.
• [45]Kamal AM, Salama OA, El Saied KM: Changes in amino acids profile and camel milk protein during the early lactation. Int J Dairy Sci 2007, 2:226-234.
• [46]Mohamed BE, Idam NZ: Effect of camel milk on plasma lipid profile of hypercholesteremic rats. OJVRTM 2011, 15:314-317.
• [47]Alhomida AS, Junaid MA, A-Jafari AA: Total, free, short-chain and long-chain acyl carnitine levels in Arabian camel’s milk (Camelus dromedarius). J Ocul Pharmacol Ther 1997, 13:381-387.
• [48]Karanth J, Jeevaratnam K: Effect of dietary lipid, carnitine and exercise on lipid profile in rat blood, liver and muscle. Indian J Exp Biol 2009, 47:748-753.
• [49]Ziamajidi N, Khaghani S, Hassanzadeh G, Vardasbi S, Ahmadian S, Nowrouzi A, Ghaffari SM, Abdirad A: Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol 2013, 58:198-209.
• [50]Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51:371-379.
• [51]Barbagallo M: Effects of vitamin E and glutathione on glucose metabolism: Role of magnesium. Hypertension 1999, 34:1002-1006.
• [52]Salami M, Moosavi-Movahedi AA, Ehsani MR, Yousefi R, Haertlé T, Jean-Marc Chobert JM, Razavi SH, Henrich R, Balalaie S, Ebadi SA, Pourtakdoost S, Niasari-Naslaji A: Improvement of the antimicrobial and antioxidant activities of camel and bovine whey proteins by limited proteolysis. J Agric Food Chem 2010, 58(6):3297-3302.
• [53]Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S: Effects of vitamin E treatment on peroxisome proliferator-activated receptor alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007, 37:229-235.
• [54]Al-Fartosi KG, Khuon OS, Al-Tae HI: Protective role of camel's milk against paracetamol induced hepatotoxicity in male rats. JPBMS 2011, 2:1795-1799.
• [55]Darwish HA, Abd Raboh NR, Mahdy A: Camel's milk alleviates alcohol-induced liver injury in rats. Food Chem Toxicol 2012, 50(5):1377-83.
• [56]Wangoha J, Faraha Z, Puhana Z: Iso-electric focusing of camel milk proteins. Int Dairy J 1998, 8:617-621.
• [57]Abd El-Mageed NM: Hepatoprotective effect of feeding celery leaves mixed with chicory leaves and barley grains to hypercholesterolemic rats. Pharmacogn Mag 2011, 7(26):151-156.
• [58]Luo Q, Cai Y, Yan J, Sun M, Corke H: Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci 2004, 26(2):137-149.
• [59]Baumrucker CR, Errondu NE: Insulin like growth factor (IGF) system in the bovine mammary gland and milk. J Mammary Gland Biol Neoplasia 2000, 5:53-55.